<DOC>
	<DOCNO>NCT01003912</DOCNO>
	<brief_summary>The purpose study determine safe administer unrelated umbilical cord blood pregnant woman first trim pregnancy fetus know diagnosis certain lysosomal storage disease . These disease know cause severe irreversible neurological disability early infancy lethal childhood .</brief_summary>
	<brief_title>Fetal Umbilical Cord Blood ( UCB ) Transplant Lysosomal Storage Diseases</brief_title>
	<detailed_description>The purpose study determine safety first trim fetal stem cell therapy use unrelated donor partially HLA-matched stem progenitor cell derive human umbilical cord blood treatment select lysosomal storage disease know cause severe irreversible neurological disability early infancy lethal childhood . This study design prospective phase I open-label single center trial . It design ass safety feasibility administration ALD-601 UCB cell first trim fetus know affected lethal lysosomal storage disease . The sample size 12 patient enrol cohort size 3 . Safety measure monitor independent DSMC 4 cohort prior proceed next cohort . Biological parent consider therapy HLA testing , mutation analysis disease status , psychological counseling . Mothers ultrasounds gestational age chorion villus test mutation analysis Krabbe , MLD , Tay Sachs , Sandhoff , PMD ( whichever appropriate ) . A crown-rump length determine day schedule transfer . The fetal weight calculate formula : Y ( kg ) = ( 2.9026 x 10-1 ) ( X 2.6528 ) . The estimated fetal weight gestational age would 0.5 ounce 14 gram . A suitably match unrelated umbilical cord blood identify 20 % portion manipulate isolation ALD-601 cell . ALD-601 ( ALDHbr ) cell isolate high speed flow sort FACSAria ( BD Biosciences ) . Upon completion sort , ALD-601 UCB cell count , viability determine , cellular composition sample measure analytical flow cytometry use fluorescence antibody lineage marker T-cells , granulocytes , monocyte , erythrocyte . The content ALDHbr cell also confirm analytical flow cytometry . A dose 1 x 105 - 2 x 106 cells/kg estimate fetal weight suspend 300 microliters Cellgenix Stem Cell Medium ( CellGenix , Inc. ) . Release criterion allow maximum 5 x 104 T cells/kg . If sort sample contains great 5 x 104 T cells/kg re-sorted use FACSAria re-evaluated cell number , viability , cellular content . Sterility test include Bac-T/ALERT culture , endotoxin measurement ( LAL ) , gram stain . After meet criteria product release , ALD-601 transport 2-8 degree C validate cooler Duke release Stem Cell Laboratory . Duke personnel transport cooler contain ALD-601 product ultrasound suite , medical team allow ALD-601 warm briefly room temperature prior injection . Under continuous ultrasound guidance , 22-gauge X 5 inch procedure needle use puncture fetal peritoneal cavity . 100 microliters sterile saline instill confirm intraperitoneal placement . The stem cell infusion inject needle follow injection 200 microliters ( dead space needle : 60 microliters ) displace cell dead space needle . An ultrasound perform 24 hour later confirm fetal viability . A subsequent ultrasound undertaken 18 week gestation confirm viability , ass detail fetal anatomy adequate serial fetal growth .</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Lysosomal Storage Diseases</mesh_term>
	<criteria>Fetus know enzymatic , possible , mutation diagnosis select lysosomal storage disease , history enzymatic mutation diagnosis previously affect family member . Krabbe disease Infantile metachromatic leukodystrophy disease ( MLD ) Tay Sachs Sandhoff ( GM2 gangliosidoses ) disease PelizaeusMerzbacher disease ( PMD ) . Both parent `` risk '' genotype Both parent agree psychological counseling prior CVS Both parent agree delivery subject Duke University Gestational age &lt; 9 week sure menstrual dating ultrasound natural pregnancy . Singleton fetus No evidence abnormal nuchal thicken preliminary ultrasound prior chorion villus biopsy Pregnancy vitro fertilization Evidence nuchal translucency &gt; 3.0 mm time ultrasound chorion villus biopsy . HIV , hepatitis C hepatitis B positive maternal status Active infection mother time schedule CVS cell injection determine clinical practice</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Inborn Errors Metabolism</keyword>
	<keyword>Krabbe</keyword>
	<keyword>Infantile metachromatic leukodystrophy disease</keyword>
	<keyword>MLD</keyword>
	<keyword>Tay Sachs</keyword>
	<keyword>Sandhoff</keyword>
	<keyword>GM2 gangliosidoses</keyword>
	<keyword>Pelizaeus-Merzbacher disease</keyword>
	<keyword>PMD</keyword>
</DOC>